BioCentury
ARTICLE | Clinical News

Lundbeck’s Lu AF35700 misses schizophrenia endpoint

October 25, 2018 11:01 PM UTC

The first Phase III trial from H. Lundbeck A/S (CSE:LUN) to read out since CEO Deborah Dunsire took the helm last month has missed its primary endpoint. Lundbeck slid DKK108.90 (27%) to DKK300 on Thursday when it reported that Lu AF35700 missed the primary endpoint in the Phase III DAYBREAK trial for treatment-resistant schizophrenia.

Dunsire become president and CEO on Sept. 1, filling a position that became vacant when Kåre Schultz resigned in September 2017. CFO Anders Götzsche had been serving as interim CEO since November 2017...